Industrial Biotechnology Innovation Cluster

产业生物技术创新集群

• 批准号: EP/Y024168/1
• 负责人: Aline Miller
• 金额: $ 666.83万
• 依托单位: University of Manchester
• 依托单位国家: 英国
• 项目类别: Research Grant
• 财政年份: 2024
• 资助国家: 英国
• 起止时间: 2024 至 无数据
• 项目状态: 未结题
• 来源: https://gtr.ukri.org/projects?ref=EP%2FY024168%2F1
• 关键词: Industrial; Biotechnology; Innovation; Cluster

Industrial Biotechnology (IB) is a set of cross-disciplinary technologies that uses biological resources for producing and processing everyday products such as food, fuels, and medicines. The field is poised for dramatic growth and has the potential to disrupt markets worth more than £34bn in the UK alone. A confluence of consumer demand, Government carbon emission targets, feedstock production efficiencies, fundamental and technical innovation has created a perfect situation for the industry to significantly expand. This paradigm shift capitalises on the strengths of a vast range of scientific and engineering disciplines which form the foundation for leveraging the rapid, specialised, and competitive growth of the sector. Industrial Biotechnology is an area in which the North-West (NW) of England has critical mass and is rapidly emerging as a world leading cluster. The region is home to some of the world's biggest healthcare and biomanufacturing companies, including AstraZeneca, Teva, Croda and Unilever, and the first commercial production of a biologic was in Speke with Eli Lilly's manufacture of insulin. The NW is home to several SME innovation zones, including Daresbury, Liverpool Knowledge Quarter and Alderley Park, which is the UK's largest single site life science campus. IB in the region employs 25,000 people and has a turnover of over £6Bn. The HEI sector is also thriving and recognised for its internationally leading IB research and unique facilities, purpose-built for innovation. Most recently demonstrated by the University of Manchester's Queens Anniversary Prize for higher education, which recognised the world-leading biotechnology expertise of the Manchester Institute of Biotechnology that sign-posts towards a bio industrial revolution. Translating IB to meet urgent societal needs will not happen spontaneously; an integrated strategy, cluster of translational activity and innovation ecosystem are essential. The NW has co-location of organisations, knowledge, skills and facilities which have already demonstrated they can promote connection and collaboration - enabling those in the region to operate more flexibly and productively. Here, we will concentrate and build our regional strengths in academia, business, civic partners, accelerators, investors and creatives with civil society and establish the Industrial Biotechnology Innovation Cluster (IBIC) with the aim of accelerating commercial exploitation of our outputs and delivering economic, social and scientific impact. United by a culture of ethics, diversity, and openness, the cluster will provide businesses with access to cutting-edge R&D knowledge, capabilities and infrastructure as well as innovation finance, skills training, and specialist support and advice. IBIC will be led by The University of Manchester and headquartered in the new Innovation District in Manchester - at the heart of the north's growing economy. It has been co-created with the University of Liverpool and our wider Civic and Business Partners. It is fully aligned with Greater Manchester and Liverpool Civic Partners strategies to increase the benefit and accelerate the impact of fundamental research across the region, and more broadly the UK economy and society. IBIC will enable the UK to realise its ambition to be a global biotechnology research and innovation superpower. The IBIC is expected to directly stimulate £2.5M cash and £4M in-kind co-investment, establish 150 collaborative projects, train 200+ students to enter careers within IB, create up to 100 green jobs, and establish 20+ new commercial ventures attracting a further £10M in investment to the North-West, generating as a minimum 3:1 economic return to public investment over the medium term. It will have a long-term legacy by helping establish IBIC as an independent and business-led cluster of excellence and by enabling society to overcome challenges in energy security, disease, and hunger mitigation.

工业生物技术 (IB) 是一套跨学科技术，利用生物资源生产和加工食品、燃料和药品等日常产品。该领域有望大幅增长，并有可能扰乱价值超过英镑的市场。仅在英国就有 340 亿人，消费者需求、政府碳排放目标、原料生产效率、基础和技术创新为该行业的大幅扩张创造了完美的局面，这种范式转变充分利用了广泛的科学优势。和工程学科工业生物技术领域是英格兰西北部（NW）具有重要影响力的领域，并且正在迅速成为世界领先的集群。西北地区是阿斯利康 (AstraZeneca)、梯瓦 (Teva)、禾大 (Croda) 和联合利华 (Unilever) 等世界上一些最大的医疗保健和生物制造公司的所在地，礼来 (Eli Lilly) 生产的胰岛素也是在斯皮克首次商业化生产。中小企业创新区，包括达斯伯里 (Daresbury)、利物浦知识区 (Liverpool Knowledge Quarter) 和阿尔德利公园 (Alderley Park)，这是英国在该地区最大的单一地点 IB 生命科学园区，拥有 25,000 名员工，营业额超过 60 亿英镑。其国际领先的 IB 研究和独特的设施，专为创新而设计，最近获得了曼彻斯特大学女王高等教育周年奖，该奖项表彰了世界领先的大学。曼彻斯特生物技术研究所的生物技术专业知识是生物工业革命的标志，它不会自发地发生；综合战略、转化活动集群和创新生态系统至关重要。已经证明可以促进联系和协作的组织、知识、技能和设施 - 使该地区的人们能够更加灵活和富有成效地运作。在这里，我们将集中并建立我们在学术界、商业、公民合作伙伴和加速器方面的区域优势。 ,投资者和创意人士与民间社会建立工业生物技术创新集群（IBIC），旨在加速我们的产品的商业开发，并通过道德、多样性和开放的文化团结起来，产生经济、社会和科学影响。 IBIC 将由曼彻斯特大学领导，总部位于曼彻斯特新创新区，为企业提供尖端研发知识、能力和基础设施以及创新融资、技能培训和专家支持和建议。的心它是与利物浦大学和我们更广泛的公民和商业合作伙伴共同创建的，它与大曼彻斯特和利物浦公民合作伙伴的战略完全一致，以提高整个地区的基础研究的效益和影响力。更广泛地说，IBIC 将使英国实现成为全球生物技术研究和创新超级大国的雄心。 IBIC 预计将直接刺激 250 万英镑的现金和 400 万英镑的实物共同投资。 150个合作项目，培训200多名学生进入IB职业生涯，创造多达100个绿色就业岗位，并建立20多个新的商业企业，为西北地区进一步吸引1000万英镑的投资，产生至少3:1的经济回报通过帮助 IBIC 建立一个独立的、由企业主导的卓越集群，并帮助社会克服能源安全、疾病和减轻饥饿方面的挑战，它将产生长期的影响。